Posted inDiabetes & Endocrinology news
HTD1801 Monotherapy Significantly Improves Glycemic Control and Cardiometabolic Health in Type 2 Diabetes: Results From a 56-Week Phase 3 Trial
A phase 3 trial demonstrated that HTD1801 monotherapy significantly reduces HbA1c and improves cardiometabolic and inflammatory markers in patients with inadequately controlled type 2 diabetes, with sustained effects and a favorable safety profile over 56 weeks.
